FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de peptides

Cerebrolysin

FPF-1070 / Brain-Derived Peptide Preparation

Cognitive & Neuro

Cerebrolysin is a porcine brain-derived peptide mixture consisting of low-molecular-weight neuropeptides and free amino acids obtained through standardized enzymatic proteolysis of pig brain proteins. It is approved in over 40 countries for the treatment of stroke, traumatic brain injury, and various forms of dementia, though it has not received FDA approval in the United States. Administration is exclusively via intravenous or intramuscular injection, with treatment protocols typically spanning 10-30 days.

Mécanisme d'action

Porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids. Exhibits neurotrophic activity mimicking BDNF, GDNF, NGF, and CNTF. Promotes neuronal sprouting, synaptogenesis, and neurogenesis. Reduces neuroinflammation.

Protocoles de recherche

Pour des fins de recherche uniquement. Pas de conseil médical.

Clinical protocols use 10-30ml IV infusion daily for 10-20 day cycles. Repeated every 3-6 months. Some protocols use 5-10ml intramuscularly. Not a single peptide — it is a standardized mixture.

Notes de recherche

Clinical Research Status

Cerebrolysin has been studied in numerous randomized controlled trials for acute ischemic stroke, traumatic brain injury, and vascular dementia. The CASTA trial and other large studies have shown mixed results, with some demonstrating improved functional outcomes while others failed to reach primary endpoints. It remains one of the most extensively studied neuropeptide preparations globally despite lacking FDA approval.

Key Published Findings

Research demonstrates neurotrophic activity similar to naturally occurring nerve growth factors, promoting neuronal sprouting, synaptic formation, and neurogenesis. Studies in Alzheimer's disease patients have shown improvements in cognitive function and global clinical assessments over 6-month treatment periods. Animal models consistently demonstrate reduced infarct volume and improved behavioral outcomes following induced stroke.

Safety Profile

The most common adverse effects include headache, dizziness, and injection site reactions, with serious adverse events occurring at rates similar to placebo in controlled trials. Allergic reactions are possible due to the porcine-derived nature of the product, though anaphylaxis is rare. It is contraindicated in patients with epilepsy, severe renal impairment, and known hypersensitivity to porcine proteins.

Comparison to Related Compounds

Unlike single-peptide nootropics such as Semax or Selank, Cerebrolysin is a complex mixture containing multiple bioactive fragments that may act synergistically on various neurotrophic pathways. Cortexin is a similar porcine brain-derived preparation but with distinct manufacturing processes and somewhat different peptide profiles. Compared to synthetic nootropics, Cerebrolysin's multi-target mechanism may offer broader neuroprotection but complicates mechanistic understanding.

Community Observations

Users frequently report improved mental clarity, enhanced recovery from brain injuries, and better cognitive function during treatment cycles. The requirement for IV/IM administration limits self-experimentation, and many users travel to countries where it is available over-the-counter. Cost and accessibility remain significant barriers, with some users sourcing from Eastern European or Asian pharmacies.

Moitié de vie

~Minutes (component peptides); neurotrophic effects last hours

Réconstitution

Pre-mixed injectable solution (no reconstitution)

Conservation

Lyophilisé

Room temperature up to 25C. Protect from light.

Réconstitué

Use immediately after opening ampule. Single-use only.

Statut légal aux États-Unis

Not FDA-approved (approved in 40+ other countries)

Autres noms connus

FPF-1070Brain-Derived Peptide Preparation

Questions fréquentes

Qu'est-ce que Cerebrolysin ?

Cerebrolysin is a porcine brain-derived peptide mixture consisting of low-molecular-weight neuropeptides and free amino acids obtained through standardized enzymatic proteolysis of pig brain proteins. It is approved in over 40 countries for the treatment of stroke, traumatic brain injury, and various forms of dementia, though it has not received FDA approval in the United States. Administration is exclusively via intravenous or intramuscular injection, with treatment protocols typically spanning 10-30 days.

Comment agit Cerebrolysin ?

Porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids. Exhibits neurotrophic activity mimicking BDNF, GDNF, NGF, and CNTF. Promotes neuronal sprouting, synaptogenesis, and neurogenesis. Reduces neuroinflammation.

Quel est le statut réglementaire de Cerebrolysin aux États-Unis ?

Not FDA-approved (approved in 40+ other countries)

Quelle est la demi-vie de Cerebrolysin ?

~Minutes (component peptides); neurotrophic effects last hours

Sous quels autres noms Cerebrolysin est-il connu ?

FPF-1070, Brain-Derived Peptide Preparation

Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.

Lire la déclaration complète